Unicycive Therapeutics effects 1-for-10 reverse stock split to regain Nasdaq compliance

Unicycive Therapeutics, Inc.

Reverse stock split at 1-for-10 ratio effective June 18, 2025; begins trading split-adjusted June 20, 2025.
Reduces outstanding shares from ~126.4M to ~12.6M; no fractional shares (rounded up).
CUSIP changes to 90466Y 202; symbol remains UNCY.
Board authorized reverse split on June 9, 2025; split intended to meet $1.00 minimum bid price for Nasdaq listing.
Proportional adjustments to stock options, warrants, and preferred stock conversion prices.

item 3.03item 5.03item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.